

Curriculum Vitae



Prof. Dr. med. Nadezda Basara
eMail: Nadezda.Basara@malteser.org

Geburtsort: Belgrad, Serbien
Nationalität: Deutsch
Familienstand: verheiratet
Kinder: 2 (geb. 1983 und 1988)

Beruflicher Werdegang

Januar 2011-heute

**Medizinischer Klinikverbund Flensburg (Diako und Malteser),
Akademisches Lehrkrankenhaus UKSH, Malteser St.
Franziskus Hospital, Med. Klinik I**

Chefärztin der Medizinischen Klinik I

2005 – 2010

**Leipzig, Universitätsklinikum, Med. Klinik II, Abteilung
Hämatologie / Onkologie**

- Ltd. Oberärztin
- Vorsitzende der Zentralen Arzneimittelkommission
- Sachkundige Person

1997 – 2005

Idar-Oberstein, Klinik für KMT und Hämatologie / Onkologie

- Oberärztin
- Leiterin der Herstellung

1997 Umzug nach Deutschland

1993 – 1997

Belgrad, Universitätskliniken

- Oberärztin

1988 – 1993

Belgrad, Universitätskliniken

- Assistenzärztin

1988 – 1984

Belgrad, Institut für medizinische Forschung

- Assistenzärztin

Qualitäts- management

2011

Führungskraft und Chefarztseminare Malteser Akademie

2007

JACIE (EBMT) Inspektor

2007

Hochschullehrertraining (POL)

2004

Führungskraft Seminar

Lehr- und Forschungs- aufenthalte

2003 - heute
Generalsekretärin des Qualitätszirkel, Rheinland-Pfalz

1999 - 2004
Leiter der Arbeitsgruppe Immunologische/hämatologische Diagnostik

1991
Paris, Hôpital Lariboisiere, Institut de Vesseaux et du Sang
(4 Monate Claude Bernard" Stipendiat)

- Tätigkeitsgebiet: Effekt von Heparin auf die Megakaryozytopoese unter der Leitung von Herrn Prof. Dr J. Caen

1990
Paris, Hôtel-Dieu Hôpital, Dept. of Hematology
(3 Monate Stipendiat)

- Tätigkeitsgebiet: Wirkung von Wachstumsfaktoren auf die hämatopoetischen Stammzellen unter der Leitung von Herrn Prof. Dr. J.P. Marie

1986 – 1987
Montreal, Canada, McGill University, Royal Victoria Hospital, Dept. of Hematology and Bone Marrow Transplantation
(12 Monate)

- Tätigkeit als Research Fellow im Labor der Knochenmarktransplantation und Fetal Liver Transplantation unter der Leitung von Herrn Professor Dr. Dr. Axel Fauser

Akademischer Werdegang

2019
The first **honorary member** of the Montenegrin medical chamber

2016
Visiting Professor, Universität Belgrad, Medizinisches Fakultät Serbien

2011
Visiting Professor, Universität Nis, Medizinisches Fakultät, Serbien

2011
Kiel, Christian-Albrechts-Universität zu Kiel

- Venia Legendi Professorin für das Fach Innere Medizin

**Studium
Schulbildung**

2007

Leipzig, Universitätsklinikum

- Außerplanmäßige Professorin

2005

Idar-Oberstein, Klinik für KMT und Hämatologie / Onkologie

- Fachärztin für Innere Medizin
Schwerpunkt Hämatologie / Internistische Onkologie
- Approbation

2002 – 2007

Mainz, Universität

- Umhabilitation zur Privatdozentin
- Vorlesungen, Fachbereich Medizin

2004

Idar-Oberstein, Klinik für KMT und Hämatologie / Onkologie

- Fachärztin für Innere Medizin

2001

Gleichwertigkeitsprüfung

1997

Erlaubnis zur Ausübung des ärztlichen Berufs nach § 10 der Bundesärzteordnung

1996 *Umzug nach Deutschland*

1993

Belgrad, Universitätskliniken

- Akademischer Grad – Dr. Sc. Med./Hämatologie (Habilitation)

1992

Belgrad, Universitätskliniken

- Facharzt für Hämatologie und Klinische Pharmakologie

1985

Belgrad, Universitätskliniken

- Akademischer Grad – Mr. Sc. Med./Hämatologie

1983

Belgrad, Universitätskliniken

- Staatsexamen

1976 – 1982

Belgrad, Universitätskliniken

Mitgliedschaften

- Medizinstudium

1976 – 1972

Belgrad, Staatliches Gymnasium

2008

IBMTR/AABMT

2004

BDI (Bund der Deutschen Internisten)

2002

DAG-KBT

2001

ESMO

2001

American Society of Hematology

1999

EBMT

1998

DGHO

1994

European Society of Hematology

1992

International Society of Hematology

Sprachkenntnisse

1990

International Society of Experimental Hematology

Onkologischer Editorial Board, Springer Verlag

In Schrift und Wort:

Deutsch, Englisch, Französisch, Kroatisch, Serbisch

Anlagen:

Prof. Dr. med. Nadezda Basara

Flensburg, 03.05.2021

- Verzeichnis der Studien als Principal Investigator
- Verzeichnis der Publikationen nach der Habilitationsschrift
 - Original-Veröffentlichungen (peer reviewed)
 - Übersichtsartikel
 - Publikationen in nicht „peer reviewed“ Zeitschriften
 - Kasuistiken
 - Buchbeiträge

- Wissenschaftliche Anerkennungen und Auszeichnungen
 - Lehr- und Forschungsaufenthalte
 - Mitarbeit in akademischen Gremien, wissenschaftliche Kommissionen und Gesellschaften
 - Verzeichnis von betreuten Dissertationen
- Auflistung aller Lehrveranstaltungen seit der Habilitation

Studien als Principal Investigator

Seit 2011

HOVON 150AML/AMLSG 29-18

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an *IDH1* or *IDH2* mutation, respectively, eligible for intensive chemotherapy. Principal Investigator

AMLSG 30-18 CPX351 Vyxeos

Randomized Phase III Study of Standard Intensive Chemotherapy *versus* Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics. Principal Investigator

AMLSG Viva, Phase II, randomisiert

Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-*trans* retinoic acid and pioglitazone versus standard dose azacitidine in patients \geq 60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy. Principal Investigator

COLOPREDICT PLUS 2.0

Register Retro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium I + II + III. Principal Investigator

Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung (CIRCULATE) AIO-KRK-0217. Principal Investigator

DSMM XVII

Elotuzumab (E) im Kombination mit Karfilzomib, Lenalidomid und Dexamethason (E-KrD) gegen KrD vor und nach autologe Stammzelltransplantation bei neu diagnostiziertem Multiplem Myelom. Eine Phase III Studie der Deutschen Studiengruppe Multiples Myelom Investigator

HD21 for advanced stages, Principal Investigator

GHSG AFM13 Protokoll für fortgeschrittenen, refraktäre Stadien d. M.Hodgkin
Principal Investigator

GO 29537

A Phase III multicentre randomizes open label study evaluating the efficacy and safety of atezolizumab in combination with carboplatin + nab-paclitaxel for chemotherapy-naïve patients with stage IV non squamous non small cell lung cancer. Principal investigator

AMLSG 11-08

Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). Principal Investigator

AMLSG 12-09

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. Principal Investigator

AMLSG 15-10

Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-*Trans* Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and *NPM1* Mutation. Principal Investigator

AMLSG16-10/CPKC412ADE02T

Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a *FLT3* internal tandem duplication. Principal Investigator

AMLSG BiO

Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage The AMLSG Biology and Outcome (BiO)-Project. Principal Investigator

AML 09-09

Eudra-CT 2009-011889-29 Phase III Studie zu Chemotherapien in Kombination mit All-*Trans*-Retinsäure mit oder ohne Gemtuzumab Ozogamicin bei Patienten mit AML und Mutation im Nucleophosmin 1Gen. Principal Investigator

DSMM XIV

Lenalidomide, Adriamycin, Dexamethasone (RAD) *versus* Lenalidomide, Bortezomib, Dexamethasone (VRD) For Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom. Subinvestigator

HD18 für fortgeschrittene Stadien

Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET. Subinvestigator

AIO-STO-0309 (POWER)

Eine offene, randomisierte Phase III-Studie zu Cisplatin und 5Fluorouracil mit oder ohne Panitumumab bei Patienten mit nicht-resektablem, fortgeschrittenen oder metastasierten Plattenepithelkarzinom des Ösophagus. Subinvestigator

AIO Trial KRK 0207

Optimal Maintenance Therapy with Bevacizumab after Induction in Metastatic CRC Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer. Subinvestigator

2010-2011

A randomized, multi-centre, parallel-group, open-label, Oncaspar controlled dose ranging trial of three doses of pegylated recombinant asparaginase in adult patients with newly diagnosed acute lymphoblastic leukemia. Principal Investigator

2010- 2011

A randomized, Multicentre, Phase II Trial to compare the Event-Free Survival of Clofarabine /ara-C (ClaraC) or of FLAMSA Treatment in patients with High-Risk Leukemia or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation. Principal Investigator

2009- 2011

HCT vs CT in elderly AML. Subinvestigator EBMT-Study

2008 – 2011

Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Ganzkörperbestrahlung, Principal Investigator

2007 - 2009

A Double-Blind, Randomised, Placebo-controlled Study of Two Different Schedule of Palifermin (Pre-and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) – 20050219, Subinvestigator

2006 - 2009

A Randomized double blinded placebo-controlled trial comparing Cyclosporine plus steroids with or without Myfortic as primary treatment for extensive chronic graft-versus host disease, An EBMT sponsored trial in chronic GvHD, Principal Investigator

2005 - 2009

A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with UVADEX* for the Treatment of Patients with Newly Diagnosed Acute Graft-versus-Host Disease, Subinvestigator

2003 - 2011

Prognostic factors in MUD-ALL, EBMT Protocol, Principal Investigator

1998 - 2003

Mycophenolate mofetil for the prophylaxis of acute GvHD (multicenter German protocol), Subinvestigator

1999 - 2001

Mycophenolate mofetil for the treatment of acute GvHD-EBMT Protocol, Subinvestigator

1993 – 1997

AREB Protokoll - Hospital Saint Louis, Paris, Koordinator

1992 - 1997

An open protocol for the use of Agrelin (Anagrelide) for patients with thrombocythemia" Project No 292, Principal Investigator; Prot. No 292024A, Principal Investigator Roberts Pharmaceutical Corporation (FDA approved protocol). Principal Investigator

Publikationen nach der Habilitationsschrift

Original-Veröffentlichungen (peer reviewed)

1. R. Schlenk, P.Paschka, J. Krzykalla....N.Basara....H.Döhner: Gemtuzumab Ozogamicin in NPM-1-Mutated AML: results from the prospective randomized AMLSG 09-09 Phase III Study. J Clin Oncol 2020; 38:623-632
2. DW Beelen, R. Trenschele, M.Steljes,... N.Basara...M.Markiewitz: Treosulfan or Busulfan plus Fludarabine as a conditioning treatment before allogeneic stem cell transplantation for older patients with acute myeloid leukemia or myelodysplastic syndrome: a randomised, non-inferiority, phase 3 trial. Lancet Hematology 2020; 7:e28-e39
3. S.Noepel-Duenebacke, H.Juette, IS Feder, L.Kluxen, N.Basara, Hiller W, Herzog T, Klaassen-Mielke R, Mueller L, Senkal M, Engel L, Teschendorf C, Trenn G, Verdoodt B, Wolters H, Uhl W, Reinacher-Schick A, Tannapfel A. High Microsatellite Instability (MSI-H) Is Associated With Distinct Clinical and Molecular Characteristics and an Improved Survival in Early Colon Cancer (CC); Real World Data From the AIO Molecular Registry Colopredict Plus. Z Gastroenterol. 2020 Jun;58(6):533-541
4. U. Schönermarck, W.Ries, B.Schröppel, ... N.Basara,... CS Haas: Relative incidence of thrombotic thrombocytopenic purpura and hemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2019; 13: 208-216
5. C. Grohe, W. Gleiber, S. Haas, C. Losem, H. Mueller-Huesmann, M. Schulze, C.Franke, N.Basara, J. Atz, R. Kaiser: Nintedanib plus docetaxel after progression on immune checkpoint inhibit therapy. Insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncology, 2019
6. Krefting^a, Nadezda Basara^b, W. Schütte^c, Clinical experience of immunotherapy treatment: efficacy and toxicity analysis of the compassionate use program of nivolumab in patients with advanced squamous cell non-small cell lung cancer. Oncology Research Treatment 2019
7. S.K.Metzelder, T.Schroeder, M.Lübbert,...N.Basara...A.Burchert: Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer 2017; 86:233-239
8. M. Koenigsmann, J. Casper, C. Kahl, D. Niederwieser, N. Basara, et al. Risk-adapted high-dose therapy with autologous and allogeneic stem cell transplantation for relapsed or refractory aggressive non-Hodgkin lymphoma. Results of a prospective phase II trial. Bone Marrow Transplant 2014; 49:410-415
9. M.Killig, B.Friedrichs, J.Meisig,... N.Basara,..Ch. Romagnani. Tracking in vivo dynamics of NK cell transferred in patients undergoing stem cell transplantation. Eur J Immunology 2014; 1-15
10. S.Kirschey, T.Flohr, H.W.Wolf, N.Frickhofen,M.Gramatzki, H.Link, N.Basara, et.al. Rituximab combined with Dexamethasone followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicenter study. British Journal of Haematology 2014;168:234
11. N.Basara, A metastatic colorectal carcinoma: a curative approach ?. ACI 2014
12. S. Kirschey, T.Flohr, HW Wolf,... N.Basara...G.Hess: Rituximab combined with Dexamethasone followed by high dose therapy as salvage therapy in patients with relapsed or

refractory B-cell lymphoma: mature results of a phase II multicenter study. *British Journal of Hematology* 2014;13234

13. M. Koenigsmann, J. Casper, C. Kahl, N. Basara, et al. Risk-adapted high-dose therapy with autologous and allogeneic stem cell transplantation for relapsed or refractory aggressive non-Hodgkin lymphoma. Results of a prospective phase II trial. *Bone Marrow Transplantation* 2014; 49, 410-415
14. W. H. Krüger, C. Hirt, N. Basara, et al. Allogeneic stem cell transplantation for mantle cell lymphoma – final report from the prospective trials of the East German Study Group Hematology/Oncology. *Ann Hemotol* 2014;93:1587
15. N. Basara, M. Labopien, R. Arnold, M. Eder, L. Volin, A. Zander, D. Beelen, H. Sengelojev, C. Faul, J. Holowiecki, M. Mohty, V. Rocha. Unrelated allogeneic stem cell transplantation with myeloablative conditioning in adults with acute lymphoblastic leukemia in remission: peripheral blood or bone marrow. *Leukemia* (submitted)
16. SK Metzelder, T. Schroeder, A. Finck, S.Scholl,... N. Basara...A. Burchert. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo immune effects to induce sustained responses. *Leukemia* 2012; 26:2353-2359
17. N. Gökbüget, N. Basara, H. Baurmann, J. Beck, M. Brüggemann, D. Hoelzer: High single drug activity of Nelarabine in relapsed T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) offers curative option with subsequent stem cell transplantation. *Blood* 2011;118:3504-3511
18. C. Friedrichs, C. Gentilini, N. Basara, C. Pfrepper, D. Niederwieser, L. Uharek. Early transfer of highly purified alloreactive CD56+CD3- NK-cells after haploidentical stem cell transplantation: promising results of a phase I study. *JCI* (submitted)
19. HK Al-Ali, M.Bourgeois,R.Krahl,E.Edel,S.Leiblein,W.Poenisch,N.Basara, et.al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2011;46:1296-02
20. H.Hübel, MM Fresen, H.Salwender,N.Basara, et.al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programm. *Bone Marrow Transplant* 2011;46:1045-1052
21. M. Schmidt-Hieber, J. Schwender, W. Heinz, T. Zabelina, J. Kuehl, S. Mousset, S. Schuettrumpf, C. Junghanss, G. Silling, N. Basara, S. Neuburger, E. Thiel, I.W. Blaus: Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. *Haematologica* 2011;96:142-149
22. C. Michael, U. Bierbach, K. Frenzel, T. Lange, N. Basara, D. Niederwieser, Ch. Mautz-Körholz and Preiss, R. Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients.*Antimicrobial Agents and Chemotherapy* 2010;54:3225-3232
23. C. Michael, U. Bierbach, K. Frenzel, T. Lange, N. Basara, D. Niederwieser, Ch. Mautz-Körholz and Preiss, R. Determination of Saliva Trough Levels for Monitoring Voriconazole Therapy in Immunocompromised Children and Adults. *The Drug Monit* 2010,32:194-199
24. N. Basara, A. Schulze, U. Wedding et al for the OSHO Study Group: Early related or unrelated hematopoietic cell transplantation results in higher overall survival and leukemia free survival compared to conventional chemotherapy in high risk patients with acute myeloid leukaemia (AML). *Leukemia* 2009; 23:635-640

25. O. Ringden, M. Labopin, G. Ehninger, D. Niederwieser, R. Olsson, N. Basara, et al. Reduced intensity Conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. *J Clin Onc* 2009; 27:4570-4577
26. D. Niederwieser, T. Lange, M. Cross, N. Basara, H. Al-Ali. Reduced intensity conditioning (RIC) hematopoietic cell transplants in elderly patients with AML. *Best Practice & Research Clinical Haematology* 2006;19:825-838
27. Y. Belkacémi, M. Labopin, Ch. Hennequin, S. Hoffstetter, R. Mungai, M. Wygoda, M. Lundell, C. Aktinson, F. Lorchel, C. Durdux, N. Basara. Reduced-intensity conditioning regimen using low dose total body irradiation prior allogeneic transplant for hematologic malignancies: experience from the European blood and marrow transplant group. *Int J Radiation Oncology* 2007;67:544-551
28. B. Wassmann, H. Pfeifer, M. Stadler, M. Bornhäuser, G. Bug, U.J. Scheuring, P. Brück, M. Stelljes, R. Schwerdtfeger, N. Basara, J. Perz, D. Bunjes, G. Ledderose, R. Mahlberg, A. Binckebanck, H. Gschaidmeier, D. Hoelzer and O.G. Ottmann on behalf of the German Multicenter ALL Study Group (GMALL). Early Molecular Response to Post-Transplant Imatinib determines Outcome in MRD-Positive Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL). *Blood* 2005;106:458-463
29. N. Basara, H. Baurmann, K. Kolbe, A. Yaman, M. Labopin, A. Burchardt, Ch. Huber, A.A. Fauser, R. Schwerdtfeger. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: Results from the multicenter German cooperative study group. *Bone Marrow Transplant* 2005;35:1011-1018
30. DW Beelen, R Trenchel, J Casper, M Freund, RA Hilger, ME Schleen, N. Basara, AA Fauser et al. Dose-escalated treosulfan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk für regimen related complications. *Bone Marrow Transplant* 2005;35:233-241
31. M. Remberger, D.W. Beelen, A.Fauser, N. Basara, O. Basu and O. Ringden: Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplanattion using unrelated donors. *Blood* 2005;105:548-551
32. D. Marisavljevic, Z.Rolovic, D.Sefer, N. Basara, D. Ilic, D.Boskovic, M.Colovic. Biological and clinical significance of clonogenic assay in patients with myelodysplastic syndromes. *Med Oncol* 2002; 19:249-59
33. M.G. Kiehl, K. Schäfer-Eckart, M. Kröger, M. Bornhäuser, N. Basara, I.W. Blau, J. Kienast, A.A. Fauser, G. Ehninger, V.W. Armstrong, M. Shipkova. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. *Transplantation proceedings* 2002;34:2922-2924
34. N. Basara, M.G. Kiehl, A.A. Fauser: Eosinophilia indicates the evolution to acute graft-versus-host disease (Letter to the editor). *Blood* 2002;100:3055
35. N. Basara, E. Roemer, L. Kraut, S. Guenzelmann, B. Schmetzer, M.G. Kiehl, A.A. Fauser: Reduced intensity preparative regimen for allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2002; 30:651-659
36. M.G. Kiehl, N. Basara: Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients (Letter to the editor). *Blood* 2001;98:1626

37. M. Remberger, O. Ringden, IW. Blau, H. Ottinger, B. Kremens, M.G. Kiehl, J. Aschan, DW Beelen, N. Basara, G. Kumlien, AA Fauser, V.Runde. No difference in GVHD, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. *Blood* 2001;98:1739-1745
38. N. Basara, S. Günzelmann, W. Willenbacher, A.A. Fauser, MG Kiehl. New immunosuppressants in BMT/GVHD. *Transplantation Proceedings* 2000;33/3 pp 2220-2222
39. N. Basara, WI Blau, MG Kiehl, E.Roemer, M.Bischoff, B. Schmetzer, D. Kirsten, S.Guenzelmann, AA Fauser: Mycophenolate mofetil in the treatment of acute and chronic GvHD in hematopoietic stem cell transplant patients. Four years experience. *Transplantation Proceedings* 2000;33/3 pp 2121-2123
40. W. Willenbacher, N. Basara, IW Blau, A.A. Fauser, MG Kiehl: Treatment of severe steroid-resistant GVHD with a monoclonal interleukin-2 receptor antagonist (Daclizumab [DC]). *British Journal of Hematology* 2001; 112:820-823
41. N. Basara, A.A. Fauser. Safety profile of mycophenolate mofetil (letter to the editor). *Bone marrow Transplantation* 2000; 26: 1362-1363 (letter to the Editor)
42. I.W. Blau, N. Basara, G. Lentini, S. Guenzelmann, D. Kirsten, B. Schmetzer, M. Bischoff, E. Roemer, M.G. Kiehl, A.A. Fauser. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. *Bone Marrow Transplantation* 2001; 27:27-34
43. E.Roemer, N. Basara, WI. Blau, Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation. Successful treatment strategies during a 5 year single center experience. *Clinical Infectious diseases* 2001; 32(1): e1-8
44. M.G. Kiehl, M. Shipkova, N. Basara, I.W. Blau, E. Schütz, V.W. Armstrong, M, Oellerich and A.A. Fauser. Mycophenolate mofetil in stem sell transplant patients in relation to plasma level of active metabolite. *Clinical Biochemistry* 2000;33(3) 203-208
45. HG Eckert, K. Kühlcke, AJ Schilz, C. Lindemann, N. Basara, AA Fauser, C. Baum. Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). *Bone Marrow Transplant (Suppl. 2)* 2000; 25:S114-S117
46. AA Fauser, N. Basara, IW Blau, MG Kiehl. A comparative study of peripheral blood stem cell vs. Bone marrow transplantation from unrelated donors (MUD): a single center study. *Bone Marrow Transplant (Suppl. 2)* 2000; 25:S27-S31
47. O. Ringden, M. Remberger, V. Runde, M. Bornhäuser, IW Blau, N. Basara, K Hölig, DW Beelen, H. Häggglud, O. Basu, G. Ehninger, AA Fauser. Faster engraftment if neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. *Bone Marrow Transplant (Suppl. 2)* 2000; 25:S6-S8
48. N. Basara, B. Schmetzer, IW. Blau, M. Bischoff, S. Günzelmann, D. Kirsten, A.A. Fauser. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study. *Bone Marrow Transplant* 2000;25:373-376
49. N. Basara, WI. Blau, MG. Kiehl, B. Schmetzer, M. Bischoff, D. Kirsten, S. Günzelmann, A.A. Fauser. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. *Clin Transplantation* 2000; 14:121-126

50. N. Basara, W. Jelkmann, B. Schmetzer, S. Günzelmann, M. Bischoff, Wl Blau, MG Kiehl, AA Fauser: Plasma thrombopoietin level in patients receiving unrelated and related bone marrow and blood stem cell transplants (Letter to the Editor). *Thrombosis and Haemostasis*, 1999 82:1771-1773
51. I.W. Blau, N. Basara, M. Bischoff, S. Günzelmann, E. Römer, D. Kirsten, B.Schmetzer, M.G. Kiehl and A.A. Fauser : Second allogeneic bone marrow transplant : successful treatment of recurrent leukaemia after first autologous transplant. *Bone Marrow Transplant* 2000; 25:41-45
52. M.G. Kiehl, N. Basara, I.W. Blau, V.W. Armstrong. Mycophenolate mofetil in der therapie und prophylaxe der GvHD bei SCT. *Transplantationmedizin* 1999;11: 112
53. S. Stosic-Grujicic, N. Basara, C. Dinarello. Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 β converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth. *Clin Lab Haem* 1999 21:173-185
54. O. Ringden, M. Remberger, V. Runde, M. Bornhäuser, Wl. Blau, K. Hölig, N. Basara, DW Beelen, H. Hägglund, O. Basu, G. Ehninger, AA Fauser. Peripheral blood stem cell (PBSC) transplantation from unrelated donor: a comparison with marrow transplantation. *Blood* 1999 94(2): 455-464
55. MD Colovic, PH Wiernik, GM Jankovic, AD Vidovic, S Janosevic, N Basara. Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. *Eur J Haematol* 1999; 62: 155-159
56. I.W. Blau, N. Basara, A.Serr, C. Seidl, E. Seifried, M. Bischoff and A.A. Fauser. A second unrelated bone marrow transplant: succesful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system. *Clin Lab Haem* 1999 21:133-138
57. N. Basara, W.I. Blau, M.G. Kiehl, E. Römer, M. Rudolphi, M. Bischoff, D. Kirsten H. Sanchez, S. Günzelmann and A.A. Fauser. The efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipients. *Transplantation Proceedings* 1998; 30 (8):4087-4089
58. N. Basara, W. Blau, E. Römer, M. Rudolphi, M. Bischoff, D. Kirsten, H. Sanchez, S. Günzelmann and A.A. Fauser. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. *Bone Marrow Transplantation* 1998; 22:61-65
59. N. Basara, P. Antunovic, D. Sefer, N. Radosevic, M. Gotic. Megakaryocyte progenitors in paroxysmal nocturna hemoglobinuria are sensitive to complement. *Eur J Haematol* 1996; 57:227-229
60. Vidovic, V. Jovanovic, A. Novak, N. Basara, G. Jankovic, M. Colovic. Agnogenic myeloid metaplasia with eosinophilia- A case report. *Srp arh celok lek* 1996;124:314-317
61. Lebeurier, N. Basara, S. Aidoudi, J. Amiral, J.P. Caen, Z.C. Han. Carbozy-terminal peptides (C1-24 and C13-24 but not C1-13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. *Br J Haematol* 1996; 92:29-34

62. N. Basara, S. Stosic-Grujicic, D. Sefer, Z. Ivanovic, P. Antunovic, P. Milenkovic. The inhibitory effect of human macrophage inflammatory protein-1a (LD78) on acute myeloid leukemia cells in vitro. *Stem Cells* 1996;14:445-241
63. N. Kraguljac, A. Bogdanovic, N. Basara. CD34 antigen expression in adult acute lymphoblastic leukemia (Letter to the editor). *Leukemia* 1996; 10:190-191
64. S. Jankovic, N. Kraguljac, N. Basara, M. Donfrid, M. Petrovic: Paroxysmal nocturnal hemoglobinuria: Golden standards vs. modern technologies (letter to the editor) *Am J Hematol* 1995;50:66
65. D. Marisavljevic, Radosevic-Radojkovic N, Basara N, Gotic M, Rolovic Z. Chronic lymphocytic leukemia associated with polycythemia vera. *Srp arh celok lek* 1995; 122:353-5
66. B. Mihaljevic, R. Nedeljkov-Jancic, M. Sretenovic, S. Jankovic, N. Radosevic, N. Kraguljac, D. Marisavljevic, N. Basara, V. Jovanovic, M. Petrovic. Acute megakaryoblastic leukemia: de novo and transformation of chronic myeloid leukemia. *Srp arh celok lek* 1995;123:164-167
67. Z. Rolovic, N. Basara, M. Gotic, D. Sefer, A. Bogdanovic. The determination of spontaneous megakaryocyte progenitors is an unequivocal test for discrimination between essential thrombocythemia and reactive thrombocytosis. *Br J Haematol* 1995;90:326-331
68. S. Stosic-Grujicic, N. Basara, P. Milenkovic, C. Dinarello. Modulation of acute myeloblastic leukemic (AML) cell proliferation and colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). *J Chemotherapy* 1995;7:67-70
69. N. Basara, N. Radosevic-Radojkovic, M. Colovic, D. Boskovic, Z. Rolovic. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in leukemic cells: correlation with induction treatment outcome. *Eur J Haematol* 1995; 55:83-87

Publications before PhD, D.Sc., Dr med. habil.

Original Papers (peer reviewed Journals)

1. N. Basara, Z. Rolovic: Megakaryocyte size in patients with chronic immune thrombocytopenia. *Iugoslav Physiol Pharmacol Acta* 24:63, 1988
2. N. Basara, L. Biljanovic-Paunovic, V. Pavlovic-Kentera: Method for growing primitive erythroid progenitors (BFU-E) from rat bone marrow. *Exp Hematol* 16:790, 1988
3. V. Pavlovic-Kentera, N. Basara, M. Jerkic, L. Biljanovic-Paunovic, G. Clemons, P. Milenkovic, D. Susic: Erythrocytosis in spontaneously hypertensive rats. *Exp Hematol* 16:950, 1988
4. L. Biljanovic-Paunovic, N. Basara, P. Milenkovic, V. Pavlovic-Kentera: Mammalian erythropoietin species specificity detected in vivo and in vitro. *Period Biol* 90:421, 1988
5. N. Basara, M. Jerkic, D. Susic, V. Pavlovic-Kentera: Megakaryocytopoiesis in spontaneously hypertensive rats. *Thrombosis Research* 53:551, 1989
6. V. Pavlovic-Kentera, N. Basara, L. Biljanovic-Paunovic, M. Vasiljevska, Z. Rolovic: Erythroid progenitors in Belgrade laboratory b/b rat. *Exp Hematol* 17:812, 1989
7. Z. Rolovic, N. Basara, L. Biljanovic-Paunovic, N. Stojanovic, N. Suvajdzic, V. Pavlovic-Kentera: Megakaryocytopoiesis in experimentally induced chronic normobaric hypoxia. *Exp Hematol* 18:190, 1990

8. N. Stojanovic, G. Jovcic, N. Basara, V. Pavlovic-Kentera: Granulopoiesis in belgrade laboratory rat. *Exp Hematol* 18:379,1990
9. Z. Rolovic, N. Basara, L. Biljanovic-Paunovic, N. Stojanovic, N. Suvajdzic, V. Pavlovic-Kentera: Abnormal megakaryocytopoiesis in Belgrade laboratory rat. *Blood* 77:456,1991
10. M. Colovic, N. Basara, N. Suvajdzic, G. Jankovic, Z. Rolovic: Dysmegakaryocytopoiesis in a patient with acute myelomonocytic leukemia and long evolution. *Hematologia* 24:113,1991
11. L. Biljanovic-Paunovic, N. Stojanovic, M. Mostarica-Stojkovic, Z.Ramic, Z. Ivanovic, N. Basara, G.K.Clemons, V. Pavlovic-Kentera: Hemopoietic growth factors in anemia of Belgrade laboratory (b/b) rat. *Exp Hematol* 20:1257,1992
12. G. Zunic, Z. Rolovic, N. Basara, M. Simovic, M. Vasiljevska: Decreased plasma proteins, increased total plasma free amino acids, and disturbed amino acid metabolism in the hereditary severe anemia of the Belgrade laboratory (b/b) rat. *Proc Soc Exp Biol Med (PSEBM)* 20:1257, 1993
13. Z. Rolovic, N. Basara, V. Pavlovic-Kentera, L. Biljanovic-Paunovic, M. Vasiljevska. The extent of anemia in Belgrade (b/b) rat. *Exp Hematol* 21:1401,1993
14. M. Gotic, N. Basara, Z. Rolovic, D. Boskovic, P. Antunovic, D. Marisavljevic, S. Brkic. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphatic leukemia with cyclosporine A: correlation between clinical and in vitro effect. *Nouv. Rev Fr Hematol* 34, 1994
15. Z.X. Shen, N. Basara, X.D. Xi, J. Caen, J.P. Maffrand, M. Pascal, M. Petitou, J.C. Lormeau, Z.C. Han. Fraxiparin, a low molecular- weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice. *Br J Haematol* 88:608, 1994
16. N. Basara, N. Radosevic-Radojkovic, M. Colovic, D. Boskovic, Z. Rolovic. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in leukemic cells: correlation with induction treatment outcome. *Eur J Haematol* 55:83-87,1995
17. S. Stosic-Grujicic, N. Basara, P. Milenkovic, C. Dinarello. Modulation of acute myeloblastic leukemic (AML) cell proliferation and colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). *J Chemotherapy* 7:67-70, 1995
18. Z. Rolovic, N. Basara, M. Gotic, D. Sefer, A. Bogdanovic. The determination of spontaneous megakaryocyte progenitors is an unequivocal test for discrimination between essential thrombocythemia and reactive thrombocytosis. *Br J Haematol* 90:326-331, 1995
19. S. Jankovic, N. Kraguljac, N. Basara, M. Donfrid, M. Petrovic: Paroxysmal nocturnal hemoglobinuria: Golden standards vs. modern technologies (letter to the editor) *Am J Hematol* 50:66, 1995
20. N. Kraguljac, A. Bogdanovic, N. Basara. CD34 antigen expression in adult acute lymphoblastic leukemia (Letter to the editor). *Leukemia* 1996; 10:190-191
21. N. Basara, S. Stosic-Grujicic, D. Sefer, Z. Ivanovic, P. Antunovic, P. Milenkovic. The inhibitory effect of human macrophage inflammatory protein-1 α (LD78) on acute myeloid leukemia cells in vitro. *Stem Cells* 14 : 445-241, 1996
22. I. Lebeurier, N. Basara, S. Aidoudi, J. Amiral, J.P. Caen, Z.C. Han. Carbozy-terminal peptides (C1-24 and C13-24 but not C1-13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. *Br J Haematol* 92:29-34, 1996

Übersichtsartikel

1. N.Basara. AdGVVEGF121.10 (GenVec). *Curr Opin Investig Drugs* 2002 2:792-795
2. S. Fruehauf, M.R. Veldwijk, S.Berlinghoff, N.Basara, C.Baum, M. Flasshove, S. Hegewisch-Becker, N. Kröger, T. Licht, T. Moritz, W. Jens Zeller, S. Laufs: Gene Therapy for Sarcoma. *Cell Tissues Organs* 2002; 172 (2): 133-44

3. N. Basara, M.G. Kiehl, A.A. Fauser. New therapeutic modalities in the treatment of graft-versus-host disease. Clinical Reviews in Oncology/Hematology 2000 vol 38/2 pp129-138
4. N. Basara, IW Blau, W. Willenbacher, MG Kiehl, AA Fauser: New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant (Suppl 2) 2000; 25:S12-S15
5. MG. Kiehl, M. Shipkova, N. Basara, WI Blau, AA Fauser. New strategies in GVHD prophylaxis. Bone Marrow Transplant (Suppl. 2) 2000; 25:S16-S19

Publikationen in nicht „peer reviewed“ Zeitschriften

1. N. Basara, S. Stosic-Grujicic, D. Sefer, N. Radosevic, Z. Ivanovic, P. Milenkovic. Inhibition of AML cell growth: comparison of the effect of MIP-1 alfa and interleukin-1 receptor antagonist. Knjiga sazetaka, X Jugoslovenski hematoloski dani, sa medjunarodnim ucescem. Niska Banja, 10-12 oktobar, 1996, 165
2. N. Suvajdzic, Z. Rolovic, N. Basara, I. Elezovic, M. Colovic. Megakariocitopoeza u bolesnika sa refraktornom hronicnom imunoloskom trombocitopenijom (riTPhr). Knjiga sazetaka, X Jugoslovenski hematoloski dani, sa medjunarodnim ucescem. Niska Banja, 10-12 oktobar, 1996, 117
3. S. Stosic-Grujicic, N. Basara, M. Dimitrijevic. Efekat leflunomida na rast celija akutne mijeloidne leukemije. Knjiga sazetaka, X Jugoslovenski hematoloski dani, sa medjunarodnim ucescem. Niska Banja, 10-12 oktobar, 1996, 153

Kasuistiken

1. N. Basara, F.-M. Rasche, T. Schwalenberg, C. Wickenhauser, M. Maier, J. Ivovic, D. Niederwieser, T. H. Lindner: Hydronephrosis resulting from bilateral ureteral stenosis: a late complication of Polyoma BK virus cystitis. Journal of Transplantation 2010;10:115
2. V. Vucinic, A. Dürr, D. Linck, A.A. Fauser and N. Basara: Isolated intraperitoneal relapse of AML after allogeneic hematopoietic stem cell transplantation in a patient with extensive chronic GVHD and full donor chimerism in bone marrow. Leukemia Lymphoma 2006; 47:1716-1718
3. D. Linck, G. Lentini, M. Tiemann, M.G. Kiehl, A. Fauser, R. Parwaresch and N. Basara: Sequential application of chemotherapy and monoclonal CD20 antibody: Successful treatment of advanced composite-lymphoma. Leukemia & Lymphoma 2005; 46:285-288
4. VAN Tran, A.A. Fauser, N. Basara, M.Kiehl. Erythropoietic recovery during treatment with Darbepoietin-alpha after impaired rHuEpo response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation (Letter). The Hematology Journal 2003; 4:456-458
5. D. Linck, N. Basara, V. Tran, V. Vucinic, S. Hermann, D. Hoelzer, AA Fauser. Peracute onset of severe tumor lysis syndrome immediately after 4Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant 2003;31:935-937
6. A. Hartert, A. Rajewski, W. Willenbacher, G. Lentini, S. Günzelmann, D. Kirsten, M. Kiehl, N. Basara, A. Fauser: Successful treatment of thrombopenia and hemolytic anemia with

ivig in a patient with lupus-like syndrome after PBSCT. Bone Marrow Transplant, 2001;27:337-340

7. P. Miljic, N. Milosevic-Jovcic, P. Antunovic, D. Boskovic, N. Basara, Z. Rolovic. Recurrent venous thrombosis in a patient with chronic lymphocytic leukemia and acquired protein S deficiency. Haematologia (Budap) 2000; 30(1):51-4
8. N. Basara, M. Bischoff, W. Blau, E. Römer, D. Kirsten, M. Rudolfi, D. Hermann, H. Sanchez, A.A. Fauser. A second unrelated bone marrow transplantation with an unrelated bone marrow donor: treatment of a patient with relapsed leukemia. Bone Marrow Transplantation 1998; 21:291-293
9. N. Basara, J. Markova*, B. Schmetzer, I.W. Blau, M.G. Kiehl, M. Bischoff, D. Kirsten, and A.A. Fauser. Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Leukemia Lymphoma 1998; 32:183-193
10. M.E. Bischoff, W. Blau, T. Wagner, W. Wagenmann, O. Dörner, N. Basara, A.A. Fauser. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplantation 1998;22:591-593

Buchbeiträge

1. N. Basara: Methadone cannabis - a medicine or a misconception? In Zoran Krivokapic: Colorectal cancer from carcinogenesis to metastases, Belgrade, (ISBN 978-86-17-19893-8) 2018
2. N. Basara, A metastatic colorectal carcinoma: a curative approach ?. ACI 2014
3. N. Basara. Definition und Einteilung von Zytostatika. R. Bäumer and A. Maiwald (Her.) Onkologische Pflege, Thieme Verlag pp 117-120 (ISBN978-3-13-143871-3) 2008
4. N. Basara. Hämatologische Erkrankungen. R. Bäumer and A. Maiwald (Her.) Onkologische Pflege, Thieme Verlag pp 281-285 (ISBN978-3-13-143871-3) 2008
5. N. Basara, E. Roemer, S. Guenzelmann, L. Kraut, B. Schmetzer, C. Seidl, E. Seifried, A.A. Fauser, M.G. Kiehl. Nonmyeloablative conditioning regimen in patients with high risk acute myeloid leukemia: unrelated and sibling allogeneic hematopoietic stem cell transplantation. Acute Leukemias IX, Basic research, experimental approaches and novel therapies. W. Hiddemann, T. Büchner, J. Ritter, M. Unterhalt, T. Haferlach (eds) Springer Verlag pp 508-513, (ISBN 3-540-43971-4) 2003
6. N. Basara. Diagnostik bei febrilen Komplikationen. Therapeutisches Vorgehen bei Fieber unklarer Genese. A.A. Fauser (ed) Uni-Med Verlag AG pp 27-42 (ISBN 3-89599-652-1) 2002
7. A. Rajewski, A. Hartert, N. Basara, I.W. Blau, E. Roemer, W. Willenbacher, G. Lentini, D. Kirsten, S. Günzelmann, M.G. Kiehl, A.A. Fauser. Allogeneic sibling and unrelated hematopoietic stem cell transplantation (HSCT) in patients with beta-thalassemia: a single center experience. 1° International Summerschool in Thalassemia, AKHAV Ed. Duran Canatan pp 99-102
8. M.G. Kiehl, N. Basara, I.W. Blau, A.A. Fauser. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. In: Transplantation in Hematology and Oncology. Springer. Eds Th. Büchner, H. Jürgens, W.E. Berdel, J. van de Loo, J. Ritter, J. Kienast, J. Vormoor. Pp 123-129 (ISBN 3-540-64898-4) 2002

9. N. Basara, S. Stosic-Grujicic, D. Sefer, Z. Ivanovic, N. Radosevic, D. Boskovic and P. Milenkovic . Modulation of acute myeloid leukemic cell growth by human macrophage inflammatory protein-1 α . In: Immunoregulation in Health and Disease. Acad. Press. Eds M.Lukic, M. Mostarica, Cuperlovic and Colic. Chapter 40, pp 421-429 (**ISBN 0-12-459460**) 1997
10. S. Stosic-Grujicic, N. Basara, C. Dinarello. Pro-IL-1 β processin is an essential step in the autocrine regulation of acute myeloid leukaemic cell growth. In: Immunoregulation in Health and Disease. Acad. Press. Eds M.Lukic, M. Mostarica, Cuperlovic and Colic. Chapter 39, pp 413-428 (**ISBN 0-12-459460**) 1997

Mitgliedschaften in Editorial Boards

- Onkologisch, Springer Verlag

Wissenschaftliche Anerkennungen und Auszeichnungen

Meine Publikationen sind mehr als 4000x in internationaler Literatur zitiert (Science Citation Index)

Vor der Habilitationsschrift habe ich 22 Publikationen in internationaler Literatur veröffentlicht

Lehr- und Forschungsaufenthalte

1986 – 1987 Royal Victoria Hospital, McGill University, Montreal

(unter der Leitung von Herrn Professor Dr. Dr. Axel Fauser).

Tätigkeit als Research Fellow im Labor der Knochenmarktransplantation und Fetal Liver Transplantation.

1990 als Stipendiat am **Hotel-Dieu Hopital, Paris**

(unter der Leitung von Herrn Prof. Dr. J.P. Marie)

Tätigkeitsgebiet: Wirkung von Wachstumsfaktoren auf die hämatopoetischen Stammzellen.

1991 als "Claude Bernard" Stipendiat, im IVS, Hopital Lariboisiere, Paris

(unter der Leitung von Herrn Prof. Dr J. Caen).

Tätigkeitsgebiet: Effekt von Heparin auf die Megakaryocytopoiese.

Mitarbeit in akademischen Gremien, wissenschaftlichen Kommissionen und Gesellschaften

Aktive Mitarbeit in der Gesellschaft „European Bone Marrow Transplantation Society, (EBMT)“ als Mitglied der Acute Leukemia Working Party (ALWP), Betreuung von prospektiver Studie bei Patienten mit akuter lymphatischer Leukämie

Organisation von Kongressen

- a) 2. International Symposium on Transplantation and Gene Therapy, Idar-Oberstein Germany, 1999
- b) International Symposium on Transplantation and Gene Therapy, Idar-Oberstein Germany, 2001
- c) International Symposium on Transplantation and Gene Therapy Idar-Oberstein Germany, 2003
- d) Sekretärin der Jahrestagung der Deutsch, Österreichischen und Schweizer Gesellschaft für Hämatologie und Onkologie, in Leipzig 2006
- e) 22. Flensburger und 1. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 19.11.2011
- f) 23. Flensburger und 2. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 17.11.2012
- g) 24. Flensburger und 3. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 16.11.2013
- h) 25. Flensburger und 4. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 15.11.2014
- i) 26. Flensburger und 5. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 14.11.2015
- j) 27. Flensburger und 6. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 12.11.2016
- k) 28. Flensburger und 7. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 11.11.2017
- l) 29. Flensburger und 8. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 10.11.2018
- m) 30. Flensburger und 9. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 09.11.2019
- n) 31. Flensburger und 10. Baltisches hämatologisch/onkologisches Symposium, Flensburg, 24.10.2020
- o) Zusätzlich diverse onkologischen Symposien

Betreute Dissertationen

1. Dominik Linck: „Vergleich von Cyclosporin-A/“short course“-Methotrexate und Cyclosporine-A/Mycophenolate Mofetil in der Prophylaxe der akuten GvHD nach allogener hämatopoetischer Stammzelltransplantation“, Mainz Juli 2005

2. **Karsten Torsten Hartmut Laabs Inauguraldissertation:** „Eosinophile Granulozyten in der akuten enteralen GvHD“, Mainz Juli 2006
3. **H. Rüsck:** „GvHD nach dosisreduzierter Konditionierung: Klinische Bedeutung der Eosinophilie“, Leipzig Juli 2009
4. **K. Schimke:** „Stammzelltransplantation: Bedeutung des Graftes“, Leipzig geplante Abgabe 2010
5. **M. Hofmann:** Stammzelltransplantation bei hochrisiko Non-Hodgkin Lymphome. Geplante Abgabe Ende 2010

Auflistung aller Lehrveranstaltungen seit der Habilitation

- 1 International Symposium on Acute Myeloid Leukemia held 1993 in Belgrad. N. Basara: Autocrine regulation of acute myeloid leukemia cell growth by IL-1 β
- 2 International Symposium "Cytokines and hemocytogenesis, immunology, tumor" held during Nov 7-10, 1994 Shanghai N. Basara: The effect of IL-1 blockade on acute myeloid leukemia progenitor colony formation and cell proliferation Abstract Book p. 33
- 3 3rd International symposium on hematology and blood transfusion. Postgraduate centre, College of medicine, King Saud University, 2002 A.A. Fauser, L.Kraut, N.Basara, M Kiehl. Prevention and treatment of acute GvHD with MMF in allogeneic stem cell transplantation. P. 46-49
- 4 3rd International symposium on hematology and blood transfusion. Postgraduate centre, College of medicine, King Saud University, 2002 A.A. Fauser, N.Basara, M Kiehl. Transplantation in Thalassemia. P 50-56
- 5 2nd International Symposium on Transplantation and Gene therapy, October 1999 Idar-Oberstein. N.Basara: New strategies in GvHD therapy. EBMT (Suppl)
- 6 2nd nationaler KMT/SZT Pflegekongreß, September 1999 N.Basara: Diagnostik der akuten Leukämien.
- 7 3rd International symposium on transplantation and gene therapy, October 2001, Idar-Oberstein. N.Basara: Mycophenolate mofetil in GvHD: State of the art. EBMT (Suppl)
- 8 1st International Symposium: Stem cell transplantation today: Benefits and Dilemmas. Belgrad 2001 November N.Basara: Treatment of AML with unrelated HSCT.
- 9 1st International Symposium: Stem cell transplantation today: Benefits and Dilemmas. Belgrad 2001 November N.Basara: Treatment of acute GvHD.
- 10 International BMT Meeting in Helsinki, Januar 2002 N.Basara: Mycophenolate mofetil in the treatment and prophylaxis of GvHD.
- 11 Club IMTIX Sanstat. The management of acute GvHD, Januar 2002 N.Basara: Mycophenolate mofetil as treatment of acute GvHD.
- 12 9. National hematology meeting with international participation. Belgrade 16.-19.10.2002 N.Basara: MUD-HSCT: Indications and results. Educational programm pp 245-254

- 13 4rd International symposium on transplantation and gene therapy, 22-24.10.2003, Idar-Oberstein. N.Basara: MUD in AML: What is the role of ATG?
- 14 Kurs "Hämatopoetische Stammzelltransplantation", Johannes Gutenberg-Universität Mainz: N.Basara: Indikation, Durchführung und Ergebnisse I, April 2002, Oktober 2003)
- 15 Kurs "Hämatopoetische Stammzelltransplantation", Johannes Gutenberg-Universität Mainz: N.Basara: Indikation, Durchführung und Ergebnisse II (May 2002. November 2002)
- 16 N.Basara: Kurs Innere Medizin WS 2005/2005, Universitätsklinikum Mainz.
- 17 N.Basara: Blockpraktikum Maligne Lymphome Universitätsklinikum Leipzig
- 18 N. Basara: Kurs Innere Medizin III, SS 2006, Universitätsklinikum Mainz
- 19 N. Basara: Kurs Innere Medizin III, Universitätsklinikum Leipzig
- 20 POST ASH Symposium Leipzig Vortrag: N. Basara: Präsentation aktueller Ergebnisse der Jahrestagung der Amerikanischen Gesellschaft für Hämatologie ASH, den 14. Januar 2006
- 21 Frühjahrsymposium des Regionalen Hämatologisch/Onkologisch Arbeitskreises, Leipzig, Vortrag: N. Basara: Neue Medikamente bei der allogenen Stammzelltransplantation, den 8.April 2006
- 22 Weiterbildung für Fachärzte: Post ASCO Symposium des Regionalen Hämatologisch/Onkologisch Arbeitskreises, Leipzig, Vortrag: N. Basara Neue Ansätze in der Prophylaxe der Schleimhauttoxizität, den 1. Juli 2006
- 23 5th Benjamin Franklin Stem Cell Workshop, Vortrag: N.Basara: Role of ATG in GvH Prophylaxis 21-23.09.06, Berlin
- 24 GvHD State of the Art, Vortrag: N. Basara: MUD-Konditionierung mit und ohne ATG, 6-7.09.06, Regensburg
- 25 N. Basara: Transplantationsdaten bei ALL, Vortrag bei der Herbsttagung der OSHO 24/25.11.2006
- 26 N. Basara, M. Labopin, T. Ruutu, A. Zander, R. Arnold, V. Rocha. Unrelated allogeneic stem cell transplantation with myeloablative preparative regimen for adult patients with acute lymphoblastic leukaemia in CR: a comparison of peripheral blood and bone marrow as a stem cell source. EBMT 25-28 March 2007
- 27 N. Basara: Nichtmaligne hämatologische Erkrankungen. Post-ASH Symposium 01/2008 Leipzig
- 28 N. Basara: Stammzelltransplantation bei CLL. Frühjahrssymposium 03/2008 Leipzig
- 29 N. Basara: PNH. Herbstsymposium 10/2008 Leipzig
- 30 N. Basara Stammzelltransplantation. Post-ASH-Symposium 01/2009
- 31 N. Basara: Acute Leukemias. Lecture at the University of Nis, 2011
- 32 N. Basara: Zielgerichtete Therapie Lecture at Medical Faculty University of Nis, 2012

- 33 N.Basara: A metastatic colorectal carcinoma: a curative approach ?. Belgrade Congress 2014
- 34 N. Basara: Checkpoint Inhibitoren in der Therapie des Lungenkarzinoms. Lecture at Medical Faculty, University of Belgrade April 2016
- 35 N.Basara: How to prevent relapse after allogeneic stem cell transplantation in acute myeloid leukemia. Lecture on 2nd Congress of Macedonian Hematology Association, University of Skopje, April 2017
- 36 N.Basara: Methadone cannabis - a medicine or a misconception? Colorectal Carcinoma. Belgrade, SANU April 2018